Cargando…

Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies

SIMPLE SUMMARY: Although conventional anti-cancer drugs have been the footstone in the fight against cancer, yet they are far from optimal due to issues related with indiscriminate destruction of normal cells, multidrug resistance, and toxicity, as a result, a more selective therapy is urgently need...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Qi-Yao, Xu, Yan-Ming, Lau, Andy T. Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600685/
https://www.ncbi.nlm.nih.gov/pubmed/32998391
http://dx.doi.org/10.3390/cancers12102783
_version_ 1783603210261364736
author Wei, Qi-Yao
Xu, Yan-Ming
Lau, Andy T. Y.
author_facet Wei, Qi-Yao
Xu, Yan-Ming
Lau, Andy T. Y.
author_sort Wei, Qi-Yao
collection PubMed
description SIMPLE SUMMARY: Although conventional anti-cancer drugs have been the footstone in the fight against cancer, yet they are far from optimal due to issues related with indiscriminate destruction of normal cells, multidrug resistance, and toxicity, as a result, a more selective therapy is urgently needed. Nanocarriers have been increasingly used in drug delivery, especially in cancer therapy. Nanocarriers can improve the therapeutic effect of drugs in cancer by enhancing the specificity and prolonging the circulating half-life of drugs. The aim of this review is to offer a detailed description of different cytotoxic drug nanocarriers and their recent progress. It is expected that this review will be of help to those who have been seeking new study directions in this field and also ones who are about to start the research on nanocarrier-based drug delivery. ABSTRACT: Conventional chemotherapy is still an important option of cancer treatment, but it has poor cell selectivity, severe side effects, and drug resistance. Utilizing nanoparticles (NPs) to improve the therapeutic effect of chemotherapeutic drugs has been highlighted in recent years. Nanotechnology dramatically changed the face of oncology by high loading capacity, less toxicity, targeted delivery of drugs, increased uptake to target sites, and optimized pharmacokinetic patterns of traditional drugs. At present, research is being envisaged in the field of novel nano-pharmaceutical design, such as liposome, polymer NPs, bio-NPs, and inorganic NPs, so as to make chemotherapy effective and long-lasting. Till now, a number of studies have been conducted using a wide range of nanocarriers for the treatment of solid tumors including lung, breast, pancreas, brain, and liver. To provide a reference for the further application of chemodrug-loaded nanoformulations, this review gives an overview of the recent development of nanocarriers, and the updated status of their use in the treatment of several solid tumors.
format Online
Article
Text
id pubmed-7600685
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76006852020-11-01 Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies Wei, Qi-Yao Xu, Yan-Ming Lau, Andy T. Y. Cancers (Basel) Review SIMPLE SUMMARY: Although conventional anti-cancer drugs have been the footstone in the fight against cancer, yet they are far from optimal due to issues related with indiscriminate destruction of normal cells, multidrug resistance, and toxicity, as a result, a more selective therapy is urgently needed. Nanocarriers have been increasingly used in drug delivery, especially in cancer therapy. Nanocarriers can improve the therapeutic effect of drugs in cancer by enhancing the specificity and prolonging the circulating half-life of drugs. The aim of this review is to offer a detailed description of different cytotoxic drug nanocarriers and their recent progress. It is expected that this review will be of help to those who have been seeking new study directions in this field and also ones who are about to start the research on nanocarrier-based drug delivery. ABSTRACT: Conventional chemotherapy is still an important option of cancer treatment, but it has poor cell selectivity, severe side effects, and drug resistance. Utilizing nanoparticles (NPs) to improve the therapeutic effect of chemotherapeutic drugs has been highlighted in recent years. Nanotechnology dramatically changed the face of oncology by high loading capacity, less toxicity, targeted delivery of drugs, increased uptake to target sites, and optimized pharmacokinetic patterns of traditional drugs. At present, research is being envisaged in the field of novel nano-pharmaceutical design, such as liposome, polymer NPs, bio-NPs, and inorganic NPs, so as to make chemotherapy effective and long-lasting. Till now, a number of studies have been conducted using a wide range of nanocarriers for the treatment of solid tumors including lung, breast, pancreas, brain, and liver. To provide a reference for the further application of chemodrug-loaded nanoformulations, this review gives an overview of the recent development of nanocarriers, and the updated status of their use in the treatment of several solid tumors. MDPI 2020-09-28 /pmc/articles/PMC7600685/ /pubmed/32998391 http://dx.doi.org/10.3390/cancers12102783 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Wei, Qi-Yao
Xu, Yan-Ming
Lau, Andy T. Y.
Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies
title Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies
title_full Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies
title_fullStr Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies
title_full_unstemmed Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies
title_short Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies
title_sort recent progress of nanocarrier-based therapy for solid malignancies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600685/
https://www.ncbi.nlm.nih.gov/pubmed/32998391
http://dx.doi.org/10.3390/cancers12102783
work_keys_str_mv AT weiqiyao recentprogressofnanocarrierbasedtherapyforsolidmalignancies
AT xuyanming recentprogressofnanocarrierbasedtherapyforsolidmalignancies
AT lauandyty recentprogressofnanocarrierbasedtherapyforsolidmalignancies